View Press Releases
-
Spaarne Gasthuis to Advance its Commitment to Patient Care with Proscia’s Software
Spaarne Gasthuis, a top clinical teaching hospital serving part of the Greater Amsterdam region, is fully digitizing its pathology practice with Concentriq® AP-Dx* from Proscia®. With this software platform, the hospital will empower its pathologists to play an even more significant role in guiding personalized treatment decisions for hundreds of thousands of patients each year.
Oct 26, 2025
-
Leading Global Cancer Center to Integrate Triomics AI Platform to Improve Clinical Trial Screening
Leading Global Cancer Center to Integrate Triomics AI Platform to Improve Clinical Trial Screening
Oct 22, 2025
-
Elixion Biotech validates its quantum-informed R&D process, proving readiness to advance precision medicines
Elixion Biotech has emerged from stealth with a breakthrough that could reshape early-stage drug discovery. In just eleven months, and without external funding, the Zurich-based therapeutics company has validated its quantum physics-informed R&D process, confirming its ability to accurately predict and identify novel drug targets. The milestone positions Elixion to advance its precision-oncology pipeline and opens the door to seed-stage investment.
Oct 22, 2025
-
Orion and Abzena Announce Exclusive Commercial License for Abzena’s Antibody
Oct 22, 2025
-
Syngene International invests in dedicated peptide laboratory and advanced automation
Oct 21, 2025
-
DNAnexus Honored with Frost & Sullivan’s 2025 Technology Innovation Leadership Award
Recognized for Global Precision Health Informatics Industry Excellence in Best Practices
Oct 21, 2025
-
Sharp Services invests $100 million in US and European facilities to increase capacity and service offerings
Oct 21, 2025
-
Ansa Biotechnologies Redefines What’s Possible in DNA Synthesis with 50 kb Sequence-Perfect Clonal Product
Ansa Biotechnologies announced the full commercial launch of its 50kb Clonal DNA product – the longest sequence-perfect synthetic DNA commercially available.
Oct 21, 2025
-
Medherant Announces Positive Results for Initial Phase 1 Clinical Trial of Testosterone Patch for Women
Oct 22, 2025
-
Oximio Welcomes Bay Area Research Logistics in Canada to the Family, Expanding Global Reach and Service Capabilities
Oximio, a global leader in supply chain solutions for the clinical research industry, is delighted to welcome Bay Area Research Logistics (BARL), Canada to the Oximio family with the agreement signed on 17th October 2025, a strategic move that strengthens Oximio’s global footprint and enhances its capabilities across the globe.
Oct 22, 2025
-
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics has initiated its Phase 2a PreciSION CF trial evaluating SION-719, the first NBD1 stabilizer, in combination with Trikafta in people with cystic fibrosis. The study marks the first time an NBD1 stabilizer has been tested alongside the current standard of care, representing a key step toward validating NBD1 as a novel, synergistic mechanism to further improve CFTR function.
Oct 20, 2025
-
KLAS Emerging Solutions Report: Ambience Healthcare Ranked #1 in Improving Clinician Experience, Top 3 in Both Improving Patient Experience and Improving Outcomes
Oct 20, 2025
-
Pillar VC, ARIA, and DSIT Announce Inaugural Encode: AI for Science Fellows
18 Encode AI fellows will be embedded into cutting-edge scientific labs across the UK
Oct 19, 2025
-
Biopharma PEG Expands Monodispersed Azide-PEG Portfolio to Advance Bioconjugation and Drug Delivery Research
Biopharma PEG Scientific Inc. has expanded its portfolio of monodispersed azide-PEG derivatives to support bioconjugation, ADC linker development, and nanoparticle surface modification. The company now offers GMP-standard manufacturing from milligram to 100-kilogram scale, ensuring consistency and scalability for research and preclinical use.
Oct 20, 2025
-
Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral
Open-science research initiative, COVID Moonshot and the AI-driven Structure-enabled Antiviral Platform (ASAP) consortium, delivered a promising pre-clinical candidate 2,000 new compounds generated for the programme are now available from Enamine’s catalogue
Oct 20, 2025
-
KLIFO Receives Regulatory Approval for New State-of-the-Art Clinical Trial Supply Facility in Copenhagen
Oct 20, 2025
-
FDB Announces First MCP Server for AI Clinical Decision Support and Other Medication Workflow Automation
FDB Announces First MCP Server for AI Clinical Decision Support and Other Medication Workflow Automation
Oct 15, 2025
-
DPYD Safety Update: Reducing the Risk of Critical or Fatal Chemotherapy Side Effects
Oct 15, 2025
-
Ensera launches as new brand identity for SteriPack
Oct 16, 2025
-
Brook.ai Secures $28 Million in Series B Funding, Led by UMass Memorial Health and Morningside, to Accelerate Next Phase of Growth and Innovation in Remote Care
Brook.ai Secures $28 Million in Series B Funding, Led by UMass Memorial Health and Morningside, to Accelerate Next Phase of Growth and Innovation in Remote Care
Oct 15, 2025


